Literature DB >> 11368985

Implanon contraceptive implants: effects on carbohydrate metabolism.

A Biswas1, O A Viegas, H J Coeling Bennink, T Korver, S S Ratnam.   

Abstract

The objective of the study was to assess the possible differences in effects of Implanon and Norplant implants on carbohydrate metabolism. This is a 2-year open randomized study of 80 implant (Implanon and Norplant) acceptors. Oral glucose tolerance test (OGTT) was performed before implant insertion and at 6, 12, and 24 months after implant insertion. Glycosylated hemoglobin A(1)C was measured in fasting samples and plasma samples during OGTT were tested for glucose and insulin levels. There was a significant increase in the area under the curve for both glucose and insulin during OGTT within each group with increasing duration of use. However, there was no significant change in the fasting plasma glucose values. There was no significant difference in the carbohydrate parameters between the two groups during implant use, except for a minimal but statistically significant rise in fasting glycosylated hemoglobin A(1)C levels at 24 months in the Implanon group. Both implants appear to induce mild insulin resistance but no significant change in serum glucose levels. These alterations in carbohydrate metabolism should have no clinical significance in healthy women.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11368985     DOI: 10.1016/s0010-7824(01)00182-2

Source DB:  PubMed          Journal:  Contraception        ISSN: 0010-7824            Impact factor:   3.375


  5 in total

1.  Bath Breakfast Project (BBP)--examining the role of extended daily fasting in human energy balance and associated health outcomes: study protocol for a randomised controlled trial [ISRCTN31521726].

Authors:  James A Betts; Dylan Thompson; Judith D Richardson; Enhad A Chowdhury; Matthew Jeans; Geoffrey D Holman; Kostas Tsintzas
Journal:  Trials       Date:  2011-07-08       Impact factor: 2.279

2.  Differential off-target glucocorticoid activity of progestins used in endocrine therapy.

Authors:  Maleshigo Komane; Chanel Avenant; Renate Louw-du Toit; Donita J Africander; Janet P Hapgood
Journal:  Steroids       Date:  2022-03-07       Impact factor: 2.760

3.  Pharmacophore modeling for identification of anti-IGF-1R drugs and in-vitro validation of fulvestrant as a potential inhibitor.

Authors:  Samra Khalid; Rumeza Hanif; Ishrat Jabeen; Qaisar Mansoor; Muhammad Ismail
Journal:  PLoS One       Date:  2018-05-22       Impact factor: 3.240

4.  An Update on Contraception in Polycystic Ovary Syndrome.

Authors:  Seda Hanife Oguz; Bulent Okan Yildiz
Journal:  Endocrinol Metab (Seoul)       Date:  2021-04-15

Review 5.  Safety and Benefits of Contraceptives Implants: A Systematic Review.

Authors:  Morena Luigia Rocca; Anna Rita Palumbo; Federica Visconti; Costantino Di Carlo
Journal:  Pharmaceuticals (Basel)       Date:  2021-06-08
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.